J Pathol Transl Med.  2020 Mar;54(2):184-187. 10.4132/jptm.2019.11.07.

Primary carcinoid tumor in the external auditory canal

• Chung DH
• Han GC
• Kim NR

• KMID: 2501609
• DOI: http://doi.org/10.4132/jptm.2019.11.07

Abstract

A 39-year-old man visited the department of otolaryngology due to an ongoing hearing disturbance that had lasted for 1 year. Temporal bone computed tomography revealed soft tissue density nearly obliterating the left external auditory canal (EAC). The mass was composed of sheets of round tumor cells containing moderate amounts of fine granular cytoplasm and salt and pepper chromatin. Neither mitosis nor necrosis was found. The Ki-67 proliferation index was less than 2%. Cells were positive for CD56 and synaptophysin but negative for chromogranin, cytokeratin (CK) 20, and CK7. Based on these findings, the tumor was diagnosed as a carcinoid tumor, well differentiated neuroendocrine carcinoma, grade 1 (G1) according to current World Health Organization (WHO) classification of head and neck tumors; and a neuroendocrine tumor, G1 according to neuroendocrine neoplasm (NEN)-2018 WHO standard classification. He remained free of local recurrence and metastasis after 20 months of follow up. To date, only six cases of primary NENs in the EAC have been reported. Metastatic tumor should be included in the differential diagnoses. Because of its rarity, the prognosis and treatment have not yet been clarified.

Keyword

Carcinoid tumor; Neuroendocrine neoplasms; Carcinoma, neuroendocrine; External auditory canal

Figure

• 

  Fig. 1. Myringoscopy revealed a grayish-colored firm mass obliterating the left external auditory canal (A), and temporal bone computed tomography revealed soft tissue density (arrow) at the external auditory canal (B).

• 

  Fig. 2. Low-power view revealed small uniform tumor cells arranged in cords, trabecular, and nested patterns (A). Tumor cells were strongly positive for synaptophysin (B).

Reference

1. Pelosi S, Koss S. Adenomatous tumors of the middle ear. Otolaryngol Clin North Am. 2015; 48:305–15.

2. Manipoud P, Mom T, Kemeny JL, Fouilloux G, Lafaye M. Cutaneous neuroendocrine carcinoma of the external ear canal. Ann Otolaryngol Chir Cervicofac. 1994; 111:111–4.

3. Litofsky NS, Smith TW, Megerian CA. Merkel cell carcinoma of the external auditory canal invading the intracranial compartment. Am J Otolaryngol. 1998; 19:330–4.

4. Mahalingam M, Kveaton JF, Bhawan J. Cutaneous neuroendocrine adenoma: an uncommon neoplasm. J Cutan Pathol. 2006; 33:315–7.

5. Palma S, Cavazzini L, Bovo R, et al. Merkel cell tumour of the external ear: report of a case. Auris Nasus Larynx. 2007; 34:229–32.

6. Li YK, Chi FL, Wang SY, Wang WQ, Yang JM, Huang YB. Cutaneous neuroendocrine carcinoma of the external auditory canal: a case report and review of the literature. Case Rep Otolaryngol. 2012; 2012:941065.

7. McCrary HC, Faucett EA, Reghunathan S, et al. The first reported case of recurrent carcinoid tumor in the external auditory canal. Otol Neurotol. 2017; 38:114–7.

8. Perez-Ordonez B, Bishop JA, Gnepp DR, Hunt JL, Thompson LD. Neuroendocrine tumours. In : El-Naggar AK, Chan JK, Grandis JR, Takata T, Slootweg PJ, editors. WHO classification of head and neck tumours. 4th ed. Lyon: IARC Press;2017. p. 95–8.

9. Rindi G, Klimstra DS, Abedi-Ardekani B, et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol. 2018; 31:1770–86.

10. Sari S, Battal B, Akgun V, Salih Deveci M. Metastasis of breast carcinoma to the external auditory canal: report of an unusual case and literature review. J Belg Soc Radiol. 2015; 99:53–7.

11. Katabi N. Neuroendocrine neoplasms of the ear. Head Neck Pathol. 2018; 12:362–6.

12. Xu B, Chetty R, Perez-Ordoñez B. Neuroendocrine neoplasms of the head and neck: some suggestions for the new WHO classification of head and neck tumors. Head Neck Pathol. 2014; 8:24–32.

13. Bell D, El-Naggar AK, Gidley PW. Middle ear adenomatous neuroendocrine tumors: a 25-year experience at MD Anderson Cancer Center. Virchows Arch. 2017; 471:667–72.